相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
Purified recombinant fragment of TEC expressed in E. coli.
- 亚型:
Mouse IgG1
- 形态:
Each vial contains 0.1 ml ascitic fluid with 0.03% sodium azide.
- 保存条件:
Store at -20°C
- 克隆性:
单克隆
- 标记物:
见下方详细说明
- 适应物种:
H
- 保质期:
1-2年
- 抗原来源:
Purified recombinant fragment of TEC expressed in E. coli.
- 目录编号:
252915
- 级别:
超纯
- 库存:
大量
- 供应商:
Abbiotec
- 宿主:
Mouse
- 应用范围:
WB
- 浓度:
见详细说明信息
- 靶点:
TEC (3A5)
- 抗体英文名:
TEC (3A5) Antibody
- 抗体名:
TEC (3A5) Antibody
- 规格:
0.1 ml
TEC (3A5) Antibody产品详细介绍:
| 产品名称: | TEC (3A5) Antibody |
| 说明书: | 【点击查看详细说明及参考图片】 |
| 货号: | 252915 |
| 规格: | 0.1 ml |
| 产品描述: | TEC (Tyrosine-protein kinase Tec) is a member of the Tec family of non-receptor protein-tyrosine kinases containing a pleckstrin homology domain. Tec family kinases are involved in the intracellular signaling mechanisms of cytokine receptors, lymphocyte surface antigens, heterotrimeric G-protein coupled receptors and integrin molecules. They are also key players in the regulation of the immune functions. Tec kinase is an integral component of T cell signaling and has a distinct role in T cell activation. Tec may be associated with myelodysplastic syndrome. |
| 克隆类型: | Mouse Monoclonal Antibody |
| 亚型: | Mouse IgG1 |
| 免疫原: | Purified recombinant fragment of TEC expressed in E. coli. |
| 适用物种: | H |
| 应用范围: | WB |
| 应用说明: | WB: 1:500-1:2000; |
| 别名: | Tyrosine-protein kinase Tec; TEC; PSCTK4 |
| 形态: | Each vial contains 0.1 ml ascitic fluid with 0.03% sodium azide. |
| 保存条件: | Store at 4°C for short term use only. Store at -20°C for storage over 1 month. Product is guaranteed 6 months from the date of shipment. |
| 参考文献: |
ABBIOTEC产品提供质量保证,提供完善的售后和技术支持,ABBIOTEC产品正品包装:
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Thin-Layer Chromatographic Analysis of Human CYP3A-Catalyzed Testosterone 6-Hydroxylation
oxidase (11 , 13 ) and testosterone 6β-hydroxylase (14 , 15 ), as useful catalytic monitors for hepatic CYP3A In a recent study, an inhibitory antipeptide antibody against CYP3A4, which did not cross-react with cDNA-expressed CYP3A5 as judged
是B细胞发育受阻不能有效地产生抗体。 究其原因,是因XLA患者X染色体长臂(q21-22.3区带)上一个基因发生了突变,该基因的编码产物为胞质中的酪氨酸激酶Btk,全称为Bruton酪氨酸激酶(Bruton tyrosine kinase),于Tec激酶家族。btk基因的突变方式可以为点突变,也可以为DNA片段缺失。 Btk不仅参与成熟B细胞抗原识别信号的转导,并在前B细胞信号转导中起关键作用。B细胞从原B向前B分化后,出现一种称为前B细胞受体(pre-BCR)的结构
主要通过细胞色素P450(CYP450)酶催化17-氨基,17-去甲氧基格 尔德霉素(17AG)产生,后者可保持HSP90抑制活性。为了减小变异,患者使用已知CYP450系统诱导剂对17AAG的临床试验已被禁止。一个最近 的17AAG一期试验报道显示CYP3A5多态性伴随着药物清除率的变化,但无总体毒性作用。醌还原酶NQO1J有在细胞培养中代谢17AAG至对 HSP90更大抑制作用。但是,NQO1中的多态性并不影响17AAG的药物动力学或全身毒性,至少在目前为止报道的那一小群病人中没有发现
技术资料暂无技术资料 索取技术资料










